-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We lift our target to $136 from $128, 15.4x our 2027 EPS forecast. We raise our 2026 EPS estimate to $6.54 from $6.50 and retain our 2027 EPS estimate at $8.82. Teleflex reported a solid start to 2026, with first-quarter results surpassing consensus estimates for both revenue and EPS. This performance comes amid a significant corporate transformation, as Teleflex progresses with the strategic divestitures of its acute care, interventional urology, and OEM businesses. The planned sale of the acute care and interventional urology businesses received a second request for information from the U.S. FTC, indicating a more in-depth antitrust review. While TFX still expects a closing in 2H 2026, this adds a layer of uncertainty and may create a potential delay, in our view. The company announced the appointment of Jason Weidman as its new President and CEO, effective June 8, who brings 25+ years of industry experience and clears a key leadership uncertainty during this transformational period.